The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats (Q42932963)

11 November 2017

title

The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats (English)

1 reference

11 November 2017

1 reference

Achilles Anagnostopoulos

object named as

Achilles Anagnostopoulos

9

0 references

author name string

Evangelia Yannaki

1

1 reference

11 November 2017

Anastasia Papadopoulou

2

1 reference

11 November 2017

Evangelia Athanasiou

3

1 reference

11 November 2017

Panayotis Kaloyannidis

4

1 reference

11 November 2017

Argyro Paraskeva

5

1 reference

11 November 2017

Dimitris Bougiouklis

6

1 reference

11 November 2017

Panayotis Palladas

7

1 reference

11 November 2017

Minas Yiangou

8

1 reference

11 November 2017

publication date

1 November 2010

1 reference

11 November 2017

published in

Arthritis & Rheumatology

1 reference

11 November 2017

volume

62

1 reference

11 November 2017

issue

11

1 reference

11 November 2017

page(s)

3277-3288

1 reference

Development of the proteasome inhibitor Velcade (Bortezomib).

11 November 2017

cites work

1 reference

Proteasome inhibitor bortezomib for the treatment of multiple myeloma.

21 January 2018

1 reference

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process

21 January 2018

1 reference

Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib

21 January 2018

1 reference

The NF-kappa B and I kappa B proteins: new discoveries and insights

21 January 2018

1 reference

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

21 January 2018

1 reference

Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway

21 January 2018

1 reference

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis

21 January 2018

1 reference

Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis

21 January 2018

1 reference

Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation

21 January 2018

1 reference

Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis

21 January 2018

1 reference

Altered lymphocyte reactivity in rheumatoid arthritis

21 January 2018

1 reference

Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

Long term treatment of rheumatoid arthritis with rituximab

21 January 2018

1 reference

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

21 January 2018

1 reference

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

21 January 2018

1 reference

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis

21 January 2018

1 reference

Bortezomib attenuates murine collagen-induced arthritis

21 January 2018

1 reference

Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining

21 January 2018

1 reference

Autoimmune disease. a problem of defective apoptosis

21 January 2018

1 reference

Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines

21 January 2018

1 reference

Myeloma bone disease and proteasome inhibition therapies.

21 January 2018

1 reference

Inhibition of osteoblastic bone formation by nuclear factor-kappaB.

21 January 2018

1 reference

Pathogen recognition and innate immunity

21 January 2018

1 reference

The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages

21 January 2018

1 reference

Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis.

21 January 2018

1 reference

Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium

21 January 2018

1 reference

Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis

21 January 2018

1 reference

Evolving concepts of rheumatoid arthritis

21 January 2018

1 reference

An essential role of NF-kappaB in the "tumor-like" phenotype of arthritic synoviocytes

21 January 2018

1 reference

NF-kappaB regulation in the immune system

21 January 2018

1 reference

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

21 January 2018

1 reference

Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.27690

1 reference

11 November 2017

1 reference